Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease

Condition(s) studied

Investigational drug(s) / intervention(s)

Standard Therapy: • The standard conventional therapy in both groups included regular exercise in the form of any physical activity as walking, cycling, etc. for 30-45 minutes minimum 5 days per week in addition to calorie restriction in overweight and obese patients (1200-1500 and 1000-1200 kcal/day for men and women, respectively).

Erdosteine: Erdosteine is an oral mucoactive agent with antioxidant and anti-inflammatory properties that also reduces bacterial adhesiveness and enhances the effects of antibiotic therapy, all of these properties may be useful for the prevention and treatment of COPD exacerbations

Study summary

Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries (1). NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. NAFLD is characterized by excessive hepatic fat accumulation without other recognized causes of increased fat content (e.g., alcohol, virus, drugs, and autoimmunity). According to the Clinical Practice Guidelines of the European Association for the Study of the Liver, the diagnosis of NAFLD requires the exclusion of daily alcohol consumption \>30 g for men and \>20 g for women

Eligibility

Primary outcome measure(s)

• The change in the degree of steatosis in the ultrasound (US) is the primary endpoint. — 3 months
  The change in the degree of steatosis in the US is the primary endpoint.
• The change in fibrosis risk scores — 3 months
  According to the Brunt criteria, fibrosis is classified in stages from stage 0 to stage 4.

Trial sites (1)

More Tanta University trials in Egypt

Other trials for the same condition